Istaroxime oxalate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563921

CAS#: 203737-94-4 (oxalate)

Description: Istaroxime, also known as PST-2744, is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase). Na+/K+ ATPase inhibition increases intracellular sodium levels, which reverses the driving force of the sodium/calcium exchanger, inhibiting calcium extrusion and possibly facilitating calcium entry. Additionally, Istaroxime increases intracellular calcium by improving the efficacy by which intracellular calcium triggers sarcoplasmic reticulum calcium release, and by accelerating the inactivation state of L-type calcium channels, which allow for calcium influx.

Chemical Structure

Istaroxime oxalate
CAS# 203737-94-4 (oxalate)

Theoretical Analysis

MedKoo Cat#: 563921
Name: Istaroxime oxalate
CAS#: 203737-94-4 (oxalate)
Chemical Formula: C23H34N2O7
Exact Mass: 450.2366
Molecular Weight: 450.53
Elemental Analysis: C, 61.32; H, 7.61; N, 6.22; O, 24.86

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 203737-93-3 (free base)   203738-46-9 (E-isomer)   1046809-08-8 (Z-isomer)   374559-48-5 (HCl)   203737-94-4 (oxalate)    

Synonym: Istaroxime oxalate; PST2774; PST-2774; PST 2774;

IUPAC/Chemical Name: (5S,8R,9S,10R,13S,14S,E)-3-((2-aminoethoxy)imino)-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthrene-6,17-dione oxalate


InChi Code: InChI=1S/C21H32N2O3.C2H2O4/c1-20-7-5-13(23-26-10-9-22)11-17(20)18(24)12-14-15-3-4-19(25)21(15,2)8-6-16(14)20;3-1(4)2(5)6/h14-17H,3-12,22H2,1-2H3;(H,3,4)(H,5,6)/b23-13+;/t14-,15-,16-,17+,20+,21-;/m0./s1

SMILES Code: O=C([C@]1(C/C(CC[C@@]1([C@]2(CC[C@@]34C)[H])C)=N/OCCN)[H])C[C@]2([C@@]3(CCC4=O)[H])[H].O=C(C(O)=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 450.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Carubelli V, Zhang Y, Metra M, Lombardi C, Felker GM, Filippatos G, O'Connor CM, Teerlink JR, Simmons P, Segal R, Malfatto G, La Rovere MT, Li D, Han X, Yuan Z, Yao Y, Li B, Lau LF, Bianchi G, Zhang J; Istaroxime ADHF Trial Group. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. Eur J Heart Fail. 2020 Jan 23. doi: 10.1002/ejhf.1743. [Epub ahead of print] PubMed PMID: 31975496.

2: Buttà C, Tuttolomondo A, Petrantoni R, Miceli G, Pinto A. Old And New Drugs For Treatment Of Advanced Heart Failure. Curr Pharm Des. 2019 Dec 26. doi: 10.2174/1381612826666191226165402. [Epub ahead of print] PubMed PMID: 31878852.

3: Kislitsina ON, Rich JD, Wilcox JE, Pham DT, Churyla A, Vorovich EB, Ghafourian K, Yancy CW. Shock - Classification and Pathophysiological Principles of Therapeutics. Curr Cardiol Rev. 2019;15(2):102-113. doi: 10.2174/1573403X15666181212125024. Review. PubMed PMID: 30543176; PubMed Central PMCID: PMC6520577.

4: Bossu A, Kostense A, Beekman HDM, Houtman MJC, van der Heyden MAG, Vos MA. Istaroxime, a positive inotropic agent devoid of proarrhythmic properties in sensitive chronic atrioventricular block dogs. Pharmacol Res. 2018 Jul;133:132-140. doi: 10.1016/j.phrs.2018.05.001. Epub 2018 May 16. PubMed PMID: 29753687.

5: Stagno MJ, Zacharopoulou N, Bochem J, Tsapara A, Pelzl L, Al-Maghout T, Kallergi G, Alkahtani S, Alevizopoulos K, Dimas K, Calogeropoulou T, Warmann SW, Lang F, Schmid E, Stournaras C. Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells. Cell Physiol Biochem. 2017;42(4):1366-1376. doi: 10.1159/000479200. Epub 2017 Jul 14. PubMed PMID: 28704809.

6: Wallner M, Khafaga M, Kolesnik E, Vafiadis A, Schwantzer G, Eaton DM, Curcic P, Köstenberger M, Knez I, Rainer PP, Pichler M, Pieske B, Lewinski DV. Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium. Oncotarget. 2017 Jul 25;8(30):49264-49274. doi: 10.18632/oncotarget.17540. PubMed PMID: 28514771; PubMed Central PMCID: PMC5564766.

7: Alevizopoulos K, Dimas K, Papadopoulou N, Schmidt EM, Tsapara A, Alkahtani S, Honisch S, Prousis KC, Alarifi S, Calogeropoulou T, Lang F, Stournaras C. Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor. Oncotarget. 2016 Apr 26;7(17):24415-28. doi: 10.18632/oncotarget.8329. PubMed PMID: 27027435; PubMed Central PMCID: PMC5029711.

8: Ahmad S, Ahmad A, Hendry-Hofer TB, Loader JE, Claycomb WC, Mozziconacci O, Schöneich C, Reisdorph N, Powell RL, Chandler JD, Day BJ, Veress LA, White CW. Sarcoendoplasmic reticulum Ca(2+) ATPase. A critical target in chlorine inhalation-induced cardiotoxicity. Am J Respir Cell Mol Biol. 2015 Apr;52(4):492-502. doi: 10.1165/rcmb.2014-0005OC. PubMed PMID: 25188881; PubMed Central PMCID: PMC4491118.

9: George M, Rajaram M, Shanmugam E, VijayaKumar TM. Novel drug targets in clinical development for heart failure. Eur J Clin Pharmacol. 2014 Jul;70(7):765-74. doi: 10.1007/s00228-014-1671-4. Epub 2014 Apr 9. Review. PubMed PMID: 24710739.

10: Hohendanner F, Ljubojević S, MacQuaide N, Sacherer M, Sedej S, Biesmans L, Wakula P, Platzer D, Sokolow S, Herchuelz A, Antoons G, Sipido K, Pieske B, Heinzel FR. Intracellular dyssynchrony of diastolic cytosolic [Ca²⁺] decay in ventricular cardiomyocytes in cardiac remodeling and human heart failure. Circ Res. 2013 Aug 16;113(5):527-38. doi: 10.1161/CIRCRESAHA.113.300895. Epub 2013 Jul 3. PubMed PMID: 23825358.

11: Huang CL. SERCA2a stimulation by istaroxime: a novel mechanism of action with translational implications. Br J Pharmacol. 2013 Oct;170(3):486-8. doi: 10.1111/bph.12288. PubMed PMID: 23822610; PubMed Central PMCID: PMC3791988.

12: Ferrandi M, Barassi P, Tadini-Buoninsegni F, Bartolommei G, Molinari I, Tripodi MG, Reina C, Moncelli MR, Bianchi G, Ferrari P. Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. Br J Pharmacol. 2013 Aug;169(8):1849-61. doi: 10.1111/bph.12278. PubMed PMID: 23763364; PubMed Central PMCID: PMC3753840.

13: Rudiger A, Singer M. The heart in sepsis: from basic mechanisms to clinical management. Curr Vasc Pharmacol. 2013 Mar 1;11(2):187-95. Review. PubMed PMID: 23506497.

14: Aditya S, Rattan A. Istaroxime: A rising star in acute heart failure. J Pharmacol Pharmacother. 2012 Oct;3(4):353-5. doi: 10.4103/0976-500X.103705. PubMed PMID: 23326115; PubMed Central PMCID: PMC3543564.

15: Gheorghiade M, Ambrosy AP, Ferrandi M, Ferrari P. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. Discov Med. 2011 Aug;12(63):141-51. Review. PubMed PMID: 21878191.

16: Luciani P, Fevre M, Leroux JC. Development and physico-chemical characterization of a liposomal formulation of istaroxime. Eur J Pharm Biopharm. 2011 Oct;79(2):285-93. doi: 10.1016/j.ejpb.2011.04.013. Epub 2011 Apr 29. PubMed PMID: 21550400.

17: Falk SA. Anesthetic considerations for the patient undergoing therapy for advanced heart failure. Curr Opin Anaesthesiol. 2011 Jun;24(3):314-9. doi: 10.1097/ACO.0b013e3283466692. Review. PubMed PMID: 21494131.

18: Farmakis D, Filippatos G. Istaroxime: is the remedy better than the disease?: Editorial to: "Chronic istaroxine improves cardiac function and heart rate variability in cardiomyopathic hamsters" by Pietro Lo Giudice et al. Cardiovasc Drugs Ther. 2011 Apr;25(2):115-7. doi: 10.1007/s10557-011-6295-7. PubMed PMID: 21484265.

19: Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. Eur Heart J. 2011 Aug;32(15):1838-45. doi: 10.1093/eurheartj/ehr026. Epub 2011 Mar 8. Review. PubMed PMID: 21388993.

20: Hoffman TM. Newer inotropes in pediatric heart failure. J Cardiovasc Pharmacol. 2011 Aug;58(2):121-5. doi: 10.1097/FJC.0b013e3182163ba0. Review. PubMed PMID: 21386708.